Rethinking Hypertension: The Untouched "A" in the RAAS Pathway
Friday, November 6th, 2026
12:15 p.m. - 1:15 p.m. LUNCH
A Dialogue Between Nephrology and Primary Care
Join a nephrologist and a primary care specialist for an insightful clinical dialogue reviewing Canadian hypertension trends, exposing aldosterone as a silent driver of treatment failure, and uncovering its hidden organ damage to redefine care paradigms.
This learning activity is supported by AstraZeneca Canada Inc.
Objectives:
- Recognize the real-world burden of hypertension in Canada including its prevalence, control rates and importance of timely management
- Explain how aldosterone contributes to hypertension and end organ damage
- Implement streamlined approaches to optimize hypertension management
Peter J. Lin, MD, CCFP
Director Primary Care Initiatives
Canadian Heart Research Centre,
Past Associate Editor, Elsevier WebPortal
Dr. Sachin V. Pasricha, MD, ABIM, FRCPC, Certified Hypertension Specialist & Nephrologist
Complex Hypertension, Sunnybrook Health Sciences Centre and Stanford University